These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16718947)

  • 41. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine.
    Abrams P; Malone-Lee J; Jacquetin B; Wyndaele JJ; Tammela T; Jonas U; Wein A
    Drugs Aging; 2001; 18(7):551-60. PubMed ID: 11482747
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tolterodine-associated acute mixed liver injury.
    Schlienger RG; Keller MJ; Krähenbühl S
    Ann Pharmacother; 2002 May; 36(5):817-9. PubMed ID: 11978158
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring.
    Layton D; Pearce GL; Shakir SA
    Drug Saf; 2001; 24(9):703-13. PubMed ID: 11522122
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hyponatremia associated with tolterodine therapy.
    Madewell KA; Kuo P
    Am J Health Syst Pharm; 2008 Jun; 65(11):1054-6. PubMed ID: 18499879
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of combined therapy with tamsulosin and tolterodine in female patients with a maximal flow rate less than 12 ml/s.
    Kim SO; Hwang EC; Oh KJ; Kwon D; Park K; Ryu SB
    Int Urogynecol J; 2011 Oct; 22(10):1287-91. PubMed ID: 21617983
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis.
    Appell RA
    Urology; 1997 Dec; 50(6A Suppl):90-6; discussion 97-9. PubMed ID: 9426760
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Abrams P; Kaplan S; De Koning Gans HJ; Millard R
    J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Flexible dose fesoterodine in the treatment of overactive bladder (OAB).
    Tubaro A; De Nunzio C
    BJU Int; 2013 Aug; 112(3):281-2. PubMed ID: 23826839
    [No Abstract]   [Full Text] [Related]  

  • 50. Tolterodine for the treatment of overactive bladder: a review.
    Rovner ES
    Expert Opin Pharmacother; 2005 Apr; 6(4):653-66. PubMed ID: 15934891
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.
    Chapple CR; Fianu-Jonsson A; Indig M; Khullar V; Rosa J; Scarpa RM; Mistry A; Wright DM; Bolodeoku J;
    Eur Urol; 2007 Oct; 52(4):1195-203. PubMed ID: 17574730
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [A drug seeks its disease].
    Löfgren O
    Lakartidningen; 2010 Jun 2-8; 107(22):1488-9. PubMed ID: 20645604
    [No Abstract]   [Full Text] [Related]  

  • 53. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
    Chapple C
    Urologe A; 2007 Apr; 46(4):422, 424-6; author reply 426, 428. PubMed ID: 17384923
    [No Abstract]   [Full Text] [Related]  

  • 55. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*.
    Herschorn S; Heesakkers J; Castro-Diaz D; Wang JT; Brodsky M; Guan Z;
    Curr Med Res Opin; 2008 Dec; 24(12):3513-21. PubMed ID: 19032133
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tolterodine: a safe and effective treatment for older patients with overactive bladder.
    Kausar SA
    J Am Geriatr Soc; 2002 Apr; 50(4):775. PubMed ID: 11982685
    [No Abstract]   [Full Text] [Related]  

  • 57. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder.
    Abrams P
    Expert Opin Pharmacother; 2001 Oct; 2(10):1685-701. PubMed ID: 11825311
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Therapy of mixed urinary incontinence].
    Goepel M
    Urologe A; 2003 Jun; 42(6):812-7. PubMed ID: 12851773
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [An example of interactions between SSRI preparations and tolterodine?].
    von Segebaden C
    Lakartidningen; 2001 May; 98(18):2234. PubMed ID: 11402608
    [No Abstract]   [Full Text] [Related]  

  • 60. [Use of warfarin and low range INR in the prevention of recurrent venous thrombosis].
    Quintero J; Torres E; Diez-Ewald M; Arteaga-Vizcaíno M; Vizcaíno G; León M; Rodríguez Z; Fernández N
    Invest Clin; 2011 Sep; 52(3):230-8. PubMed ID: 21950194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.